Cargando…

Choice of Treatment Regimen as Add-On to Insulin in Japanese Patients with Type 2 Diabetes Mellitus: Physicians’ Perspective in a Real-World Setting, Insight from a Web Survey

INTRODUCTION: The Japanese guidelines emphasize treatment individualization and intensification with oral anti-diabetes drugs and glucagon-like peptide-1 receptor agonists (OADGs) as add-on therapy to insulin in the management of type 2 diabetes mellitus (T2DM). However, a step-wise treatment algori...

Descripción completa

Detalles Bibliográficos
Autores principales:	Imai, Kota, Murayama, Hiroki, Hirose, Takahisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6167295/ https://www.ncbi.nlm.nih.gov/pubmed/30058059 http://dx.doi.org/10.1007/s13300-018-0476-3

Ejemplares similares

Factors Influencing the Prescribing Preferences of Physicians for Drug-Naive Patients with Type 2 Diabetes Mellitus in the Real-World Setting in Japan: Insight from a Web Survey
por: Murayama, Hiroki, et al.
Publicado: (2018)

Efficacy and Safety of Vildagliptin as an Add-on to Insulin with or without Metformin in Japanese Patients with Type 2 Diabetes Mellitus: A 12-week, Double-Blind, Randomized Study
por: Hirose, Takahisa, et al.
Publicado: (2015)

Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus
por: Katsuno, Tomoyuki, et al.
Publicado: (2016)

Inpatient management of type 2 Diabetes Mellitus: Does choice of insulin regimen really matter?
por: Akhtar, Syed Tehseen, et al.
Publicado: (2014)

A Real-World, Observational Study of the Initiation, Use, and Effectiveness of Basal-Bolus or Premixed Insulin in Japanese People with Type 2 Diabetes
por: Miyoshi, Hideaki, et al.
Publicado: (2021)

Efficacy and Safety of Vildagliptin as Add-on to Metformin in Japanese Patients with Type 2 Diabetes Mellitus
por: Odawara, Masato, et al.
Publicado: (2014)

Freedom of choice adds value to public goods
por: Shi, Lei, et al.
Publicado: (2020)

Dulaglutide as an Add-on to Insulin in Type 2 Diabetes; Clinical Efficacy and Parameters Affecting the Response in Real-World Practice
por: Lee, Jiwoo, et al.
Publicado: (2019)

Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
por: Kaku, Kohei, et al.
Publicado: (2019)

Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus
por: Okada, Morihiro, et al.
Publicado: (2015)

Real‐world data on eslicarbazepine acetate as add‐on to antiepileptic monotherapy
por: Holtkamp, M., et al.
Publicado: (2016)

Simplification of complex insulin regimens using canagliflozin or liraglutide in patients with well‐controlled type 2 diabetes: A 24‐week randomized controlled trial
por: Ando, Yasuyo, et al.
Publicado: (2021)

Lixisenatide as add-on therapy to basal insulin
por: Brown, Dominique Xavier, et al.
Publicado: (2013)

Insulin Degludec in Clinical Practice: A Review of Japanese Real-World Data
por: Kaku, Kohei, et al.
Publicado: (2017)

The use of metformin as an add-on therapy to insulin in the treatment of poorly controlled type 1 diabetes mellitus in adolescents
por: Sikorskaya, Katsiaryna, et al.
Publicado: (2021)

Effects of the addition of acarbose to insulin and non-insulin regimens in veterans with type 2 diabetes mellitus
por: Wettergreen, Sara A., et al.
Publicado: (2016)

Efficacy and safety of ipragliflozin as add‐on therapy to insulin in Japanese patients with type 2 diabetes mellitus (IOLITE): a multi‐centre, randomized, placebo‐controlled, double‐blind study
por: Ishihara, Hisamitsu, et al.
Publicado: (2016)

Real-World Comparative Evaluation of Add-On Glucagon-like Peptide 1 Receptor Agonist in Type 2 Diabetes Treated with or without Insulin
por: Chou, Hsuan-Wen, et al.
Publicado: (2022)

Regimen of the Japanese Soldier
Publicado: (1888)

Discrete Choice Experiment to Understand Japanese Patients’ and Physicians’ Preferences for Preventive Treatments for Migraine
por: Seo, Jaein, et al.
Publicado: (2023)

Comparison of Patient-Led and Physician-Led Insulin Titration in Japanese Type 2 Diabetes Mellitus Patients Based on Treatment Distress, Satisfaction, and Self-Efficacy: The COMMIT-Patient Study
por: Ishii, Hitoshi, et al.
Publicado: (2021)

＜Editors’ Choice＞ Differential effects of combination therapy on the components of the risk stratification table in patients with idiopathic or heritable pulmonary arterial hypertension in a Japanese population
por: Yoshida, Masahiro, et al.
Publicado: (2021)

Treatment Costs of Basal Insulin Regimens for Type 2 Diabetes Mellitus in France
por: Detournay, Bruno, et al.
Publicado: (2020)

Use of Insulin Glargine 100 U/mL for the Treatment of Type 2 Diabetes Mellitus in East Asians: A Review
por: Hirose, Takahisa, et al.
Publicado: (2019)

Teclistamab versus real-world physician’s choice of therapy in triple-class exposed relapsed/refractory multiple myeloma
por: Krishnan, Amrita, et al.
Publicado: (2023)

ARV regimen choice and co-morbidities
por: Peters, Barry
Publicado: (2014)

Insulin versus an oral antidiabetic agent as add-on therapy in type 2 diabetes after failure of an oral antidiabetic regimen: a meta-analysis
por: Gamble, JM, et al.
Publicado: (2008)

THE INTERNET AND THE WORLD WIDE WEB: APPLICATIONS FOR FAMILY PHYSICIANS IN SAUDI ARABIA
por: Sebiany, Abdulaziz M.
Publicado: (2001)

Treatment patterns of drug-naive patients with type 2 diabetes mellitus: a retrospective cohort study using a Japanese hospital database
por: Morita, Yohei, et al.
Publicado: (2019)

Clinical outcomes of basal insulin and oral antidiabetic agents as an add-on to dual therapy in patients with type 2 diabetes mellitus
por: Cheng, Chih-Ning, et al.
Publicado: (2020)

Long‐term (52‐week) efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: An uncontrolled, open‐label extension of a phase III study
por: Kaku, Kohei, et al.
Publicado: (2020)

Managing the web of things: linking the real world to the Web
por: Sheng, Quan Z, et al.
Publicado: (2017)

A labelled discrete choice experiment adds realism to the choices presented: preferences for surveillance tests for Barrett esophagus
por: Kruijshaar, Michelle E, et al.
Publicado: (2009)

Review of basal‐plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus
por: Raccah, D., et al.
Publicado: (2017)

The Post-COVID 19 long term surveillance study sequel to an add-on Ayurveda regimen
por: Wanjarkhedkar, Pankaj, et al.
Publicado: (2022)

Modeling Pharmacokinetic Profiles of Insulin Regimens to Enhance Understanding of Subcutaneous Insulin Regimens
por: Tham, Lai San, et al.
Publicado: (2017)

Real-world cost analysis of chemotherapy for colorectal cancer in Japan: detailed costs of various regimens during the entire course of chemotherapy
por: Yajima, Shuichi, et al.
Publicado: (2016)

Conditioning regimens for allogeneic hematopoietic cell transplantation in acute myeloid leukemia: Real-world data from the Japanese registry studies
por: Yanada, Masamitsu, et al.
Publicado: (2022)

Efficacy and safety of empagliflozin as add‐on to insulin in Japanese patients with type 2 diabetes: A randomized, double‐blind, placebo‐controlled trial
por: Sone, Hirohito, et al.
Publicado: (2019)

The Physician Himself, and What He Should Add to His Scientific Acquirements
Publicado: (1883)

Cannot write session to /tmp/vufind_sessions/sess_h2qmciofgg28d3gtmjt2hhbjm0